| Andrea Austin Hancock, MSCCCSLP | |
|
509 N Carrier St, Morganfield, KY 42437-1201 | |
| (270) 389-3513 | |
| (270) 389-4706 |
| Full Name | Andrea Austin Hancock |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 509 N Carrier St, Morganfield, Kentucky |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215134200 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | KY-3169 (Kentucky) | Secondary |
| 235Z00000X | Speech-language Pathologist | 5462 (South Carolina) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Andrea Austin Hancock, MSCCCSLP Po Box 26106, Greenville, SC 29616-1106 Ph: (864) 905-9645 | Andrea Austin Hancock, MSCCCSLP 509 N Carrier St, Morganfield, KY 42437-1201 Ph: (270) 389-3513 |
News Archive
A nonsurgical treatment option for rectal cancer that preserves quality of life is safe for carefully selected patients, according to a new study comparing it with the standard operation.
Bill Clinton, the former U.S. president, is urging the United States to be more flexible in allowing money pledged for AIDS prevention to be used for low-cost generic drugs, and he has criticized U.S. drug manufacturers for pressuring the government to restrict use of those funds.
In March 2010, the Democrat-controlled Congress forced the passage of the Patient Protection and Affordable Care Act (now known as ObamaCare) over the strong objections of the majority of Americans, most of whom were either already receiving taxpayer-funded health insurance or were satisfied with their private coverage.
The Centers for Disease Control estimate that more than two million people in the United States are affected annually by hospital-acquired infections. Meanwhile, a report released in April by the Agency for Healthcare Research and Quality concluded that this problem, which is worsening, requires urgent attention.
Inspire Pharmaceuticals, Inc. announced today that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM). Denufosol is an investigational, inhaled, novel ion channel regulator currently in Phase 3 clinical development for the treatment of CF.
› Verified 3 days ago
Molly Meacham, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 414 W Mcelroy St, Morganfield, KY 42437 Phone: 270-952-3461 | |
Ms. Jennifer Marie Obert, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 509 N Carrier St, Morganfield, KY 42437 Phone: 270-389-3513 Fax: 270-389-4706 |